keyword
https://read.qxmd.com/read/37889382/pharmacokinetics-pharmacodynamics-and-efficacy-of-pemigatinib-a-selective-inhibitor-of-fibroblast-growth-factor-receptor-1-3-monotherapy-in-chinese-patients-with-advanced-solid-tumors-a-phase-i-clinical-trial
#1
JOURNAL ARTICLE
Ting Deng, Le Zhang, Yehui Shi, Guiying Bai, Yueyin Pan, Aizong Shen, Xinghua Han, Zhaoyi Yang, Mingxia Chen, Hui Zhou, Yang Luo, Shirui Zheng, Yi Ba
Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1-3 inhibitor and has demonstrated acceptable tolerability and clinical activity in advanced solid tumors in Western population. This phase I trial evaluated pharmacokinetics/pharmacodynamics (PK/PD) characteristics, preliminary safety and efficacy of pemigatinib in Chinese patients with advanced, solid tumors. Patients with unresectable advanced or metastatic solid tumors bearing FGF/FGFR1-3 alterations received oral pemigatinib at 13.5 mg once daily (QD) on a 2-weeks-on/1-week-off schedule...
October 27, 2023: Investigational New Drugs
https://read.qxmd.com/read/23682528/incidence-of-primary-colorectal-cancer-from-colonoscopy-examinations-in-patients-presenting-with-liver-mass
#2
JOURNAL ARTICLE
Siripong Sirikurnpiboon, Burin Awapittaya, Jerasak Wannaprasert
BACKGROUND: An in-patient presented with atypical primary liver mass and was suspected of having liver metastasis. One method of investigation is colonoscopy; however, there are currently no clear guidelines to indicate when this procedure should be performed. MATERIAL AND METHOD: This was a retrospective review of 6 years' data from the surgical endoscopic unit in Rajavithi Hospital. The inclusion criteria were: (1) patient presented with liver mass, (2) radiological findings (mainly from CT scan or MRI) were not typicalfor hepatocellular carcinoma (HCC), intrahepatic cholagiocarcinoma (ICGC) and other primary liver tumors...
March 2013: Journal of the Medical Association of Thailand
https://read.qxmd.com/read/21211023/expression-and-prognostic-significance-of-cancer-testis-antigens-cta-in-intrahepatic-cholagiocarcinoma
#3
JOURNAL ARTICLE
Jin-Xue Zhou, Yin Li, Sun-Xiao Chen, An-Mei Deng
BACKGROUND: Cancer-testis antigens (CTAs) are suitable targets for cancer-specific immunotherapy. The aim of the study is to investigate the expression of CTAs in intrahepatic cholagiocarcinoma (IHCC) and evaluate their potential therapeutic values. METHODS: Eighty-nine IHCC patients were retrospectively assessed for their expression of CTAs and HLA Class I by immunohistochemistry using the following antibodies: MA454 recognizing MAGE-A1, 57B recognizing multiple MAGE-A (MAGE-A3/A4), E978 recognizing NY-ESO-1, and EMR8-5 recognizing HLA class I...
January 6, 2011: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/20496550/liver-resections-for-hilar-cholangiocarcinoma
#4
JOURNAL ARTICLE
F Giuliante, F Ardito, M Vellone, G Nuzzo
Hilar cholangiocarcinoma (HC) is a rare tumor which has to be distinguished by intrahepatic cholagiocarcinoma invading hepatic hilum because the former has better prognosis then the latter. Patients with HC are difficult to manage because many challenging issues remain in the treatment of this tumour regarding correct diagnosis and therapeutic strategy. HC is resectable in about 30% of cases, but operative risk is highly influenced by septic complications of preoperative biliary drainage and by the need of major liver resection associated with biliary resection...
April 2010: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/12811216/acute-viral-cholecystitis-due-to-hepatitis-a-virus-infection
#5
JOURNAL ARTICLE
Resat Ozaras, Ali Mert, Mehmet Halit Yilmaz, Aygul Dogan Celik, Fehmi Tabak, Muammer Bilir, Recep Ozturk
Acute hepatitis A virus (HAV) infection is frequent in developing countries. Although some gallbladder abnormalities are defined during the course, an acute cholecystitis is extremely rare. We here report 2 additional cases of cholecystitis due to acute HAV infection and review the previously reported 2 cases. One of our patients was admitted with jaundice and a suspicious portal mass with a presumed diagnosis of cholagiocarcinoma. The other presented with jaundice, abdominal pain, and constitutional symptoms...
July 2003: Journal of Clinical Gastroenterology
https://read.qxmd.com/read/165715/cholagiocarcinoma-in-a-patient-previously-given-thorotrast
#6
JOURNAL ARTICLE
P K Johnson, R R Babb
The long-term effects of thorotrast administration include local granulomas, blood cell abnormalities, and cancer. To date, more than 100 cases of liver cancer have been reported in patients previously given this radioactive contrast material, with a latency period of approximately 22 years. We report such a case; the patient not only had a thorotrast-induced cholangiocarcinoma, but also showed striking morphologic changes in the red blood cells secondary to splenic dysfunction.
April 1975: American Journal of Digestive Diseases
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.